Literature DB >> 21794933

The pathophysiology of heart failure with preserved ejection fraction: from molecular mechanisms to exercise haemodynamics.

Thanh T Phan1, Ganesh Nallur Shivu, Khalid Abozguia, John E Sanderson, Michael Frenneaux.   

Abstract

The pathophysiology of HfpEF is complex. In this review we discuss the molecular aspects of HfpEF as well as the profoundly disturbed haemodynamics with particular focus on exercise haemodynamic abnormalities.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2011        PMID： 21794933     DOI： 10.1016/j.ijcard.2011.06.113

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


  22 in total

1.  The Management of Heart Failure with Preserved Ejection Fraction.

Authors:  Andrew Js Coats; Louise G Shewan
Journal:  Card Fail Rev       Date:  2015-04

2.  Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction.

Authors:  Pankaj Garg; Hosamadin Assadi; Rachel Jones; Wei Bin Chan; Peter Metherall; Richard Thomas; Rob van der Geest; Andrew J Swift; Abdallah Al-Mohammad
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 3.  Fluid dynamics of ventricular filling in heart failure: overlooked problems of RV/LV chamber dilatation.

Authors:  Ares Pasipoularides
Journal:  Hellenic J Cardiol       Date:  2015 Jan-Feb

Review 4.  Heart failure with preserved ejection fraction: emerging drug strategies.

Authors:  Fouad A Zouein; Lisandra E de Castro Brás; Danielle V da Costa; Merry L Lindsey; Mazen Kurdi; George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

Review 5.  The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction.

Authors:  Julio A Chirinos; Payman Zamani
Journal:  Curr Heart Fail Rep       Date:  2016-02

Review 6.  New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.

Authors:  Michele Senni; Walter J Paulus; Antonello Gavazzi; Alan G Fraser; Javier Díez; Scott D Solomon; Otto A Smiseth; Marco Guazzi; Carolyn S P Lam; Aldo P Maggioni; Carsten Tschöpe; Marco Metra; Scott L Hummel; Frank Edelmann; Giuseppe Ambrosio; Andrew J Stewart Coats; Gerasimos S Filippatos; Mihai Gheorghiade; Stefan D Anker; Daniel Levy; Marc A Pfeffer; Wendy Gattis Stough; Burkert M Pieske
Journal:  Eur Heart J       Date:  2014-08-07       Impact factor: 29.983

Review 7.  Medication management of chronic heart failure in older adults.

Authors:  Kannayiram Alagiakrishnan; Maciej Banach; Linda G Jones; Ali Ahmed; Wilbert S Aronow
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

Review 8.  Characterizing heart failure in the ventricular volume domain.

Authors:  Peter Lm Kerkhof
Journal:  Clin Med Insights Cardiol       Date:  2015-02-25

9.  Concept of myocardial fatigue in reversible severe left ventricular systolic dysfunction from afterload mismatch: a case series.

Authors:  Patrick Tran; Mithilesh Joshi; Prithwish Banerjee
Journal:  Eur Heart J Case Rep       Date:  2021-03-07

10.  Ergospirometry and echocardiography in early stage of heart failure with preserved ejection fraction and in healthy individuals.

Authors:  Eduardo Lima Garcia; Márcio Garcia Menezes; Charles de Moraes Stefani; Luiz Cláudio Danzmann; Marco Antonio Rodrigues Torres
Journal:  Arq Bras Cardiol       Date:  2015-07-31       Impact factor: 2.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.